Semaglutide vs Tirzepatide: GLP-1 Agonist Research Comparison
Quick Summary
Semaglutide and Tirzepatide represent the current frontier of incretin-based research. Semaglutide is a selective GLP-1 receptor agonist (FDA-approved as Ozempic/Wegovy), while Tirzepatide is the first dual GIP/GLP-1 receptor agonist (FDA-approved as Mounjaro/Zepbound). Head-to-head trials have shown meaningful differences in efficacy, making this the most clinically relevant peptide comparison in metabolic research.
Semaglutide
Research Overview Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native human GLP-1. It features an aminoisobutyric acid (Aib) substitution at position 8 for DPP-4 resistance and a C18 fatty diacid chain linked via...
Tirzepatide
Tirzepatide (also known as LY3298176) is a first-in-class, synthetic 39-amino acid linear peptide engineered as a single-molecule dual agonist for both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. [1] Developed by Eli Lilly and Company,...
Research Comparison: Semaglutide vs Tirzepatide
| Dimension | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor Targets | GLP-1 receptor (selective agonist) | GLP-1 + GIP receptors (dual agonist β first in class) |
| FDA-Approved Names | Ozempic (T2D), Wegovy (weight management) | Mounjaro (T2D), Zepbound (weight management) |
| Structure | 31 amino acids (modified GLP-1 analog with C18 fatty acid) | 39 amino acids (GIP-based backbone with GLP-1 activity) |
| Half-Life | ~7 days (weekly dosing) | ~5 days (weekly dosing) |
| Weight Loss (Highest Dose) | ~15-17% body weight (STEP trials, 2.4mg) | ~22.5% body weight (SURMOUNT-1, 15mg) |
| HbA1c Reduction | ~1.5-1.8% reduction (SUSTAIN trials) | ~2.0-2.4% reduction (SURPASS trials) |
| Cardiovascular | MACE reduction proven (SELECT trial β 20% RR) | SURPASS-CVOT ongoing; positive MACE signal expected |
| GI Side Effects | Nausea ~20%, vomiting ~5-10% | Similar nausea rates; possibly fewer with GIP component |
| Insulin Sensitivity | Moderate improvement via weight loss | Superior insulin sensitivity via direct GIP action |
| Research Volume | 10,000+ publications | 2,000+ publications (newer compound) |
Chemical Properties Comparison
| Property | Semaglutide | Tirzepatide |
|---|---|---|
| Molecular Formula | C187H291N45O59 | Cβββ HβββNββOββ |
| Molecular Weight | 4113.58 g/mol | 4813.53 Da |
| CAS Number | 910463-68-2 | 2023788-19-2 |
| Amino Acid Sequence | H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-Ξ³-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH | Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(C20 fatty diacid)-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NHβ |
| PubMed Citations | 12 referenced | 40 referenced |
Explore Full Research Profiles
Semaglutide
Research Overview Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native human GLP-1. It features an aminoisobutyric acid (Aib) substitution at position 8 for DPP-4 resistance and a C18 fatty diacid chain linked via...
Tirzepatide
Tirzepatide (also known as LY3298176) is a first-in-class, synthetic 39-amino acid linear peptide engineered as a single-molecule dual agonist for both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. [1] Developed by Eli Lilly and Company,...
More Peptide Comparisons
For Research Use Only (RUO). This comparison is for educational and informational purposes only. All products are intended solely for in-vitro research and laboratory experimentation. Products have not been approved by the FDA for human or veterinary use. Pure U.S. Peptides does not condone or encourage the use of these products for anything other than strictly defined research applications.